Accuracy of the No-Biopsy Approach for the Diagnosis of Celiac Disease in Adults: A Systematic Review and Meta-Analysis
- PMID: 38176661
- DOI: 10.1053/j.gastro.2023.12.023
Accuracy of the No-Biopsy Approach for the Diagnosis of Celiac Disease in Adults: A Systematic Review and Meta-Analysis
Abstract
Background & aims: Current international guidelines recommend duodenal biopsies to confirm the diagnosis of celiac disease in adult patients. However, growing evidence suggests that immunoglobulin A (IgA) anti-tissue transglutaminase (tTg) antibody levels ≥10 times the upper limit of normal (ULN) can accurately predict celiac disease, eliminating the need for biopsy. We performed a systematic review and meta-analysis to evaluate the accuracy of the no-biopsy approach to confirm the diagnosis of celiac disease in adults.
Methods: We systematically searched MEDLINE, EMBASE, Cochrane Library, and Web of Science from January 1998 to October 2023 for studies reporting the sensitivity and specificity of IgA-tTG ≥10×ULN against duodenal biopsies (Marsh grade ≥2) in adults with suspected celiac disease. We used a bivariate random effects model to calculate the summary estimates of sensitivity, specificity, and positive and negative likelihood ratios. The positive and negative likelihood ratios were used to calculate the positive predictive value of the no-biopsy approach across different pretest probabilities of celiac disease. The methodological quality of the included studies was evaluated using the QUADAS-2 tool. This study was registered with PROSPERO, number CRD42023398812.
Results: A total of 18 studies comprising 12,103 participants from 15 countries were included. The pooled prevalence of biopsy-proven celiac disease in the included studies was 62% (95% confidence interval [CI], 40%-83%). The proportion of patients with IgA-tTG ≥10×ULN was 32% (95% CI, 24%-40%). The summary sensitivity of IgA-tTG ≥10×ULN was 51% (95% CI, 42%-60%), and the summary specificity was 100% (95% CI, 98%-100%). The area under the summary receiver operating characteristic curve was 0.83 (95% CI, 0.77 - 0.89). The positive predictive value of the no-biopsy approach to identify patients with celiac disease was 65%, 88%, 95%, and 99% if celiac disease prevalence was 1%, 4%, 10%, and 40%, respectively. Between-study heterogeneity was moderate (I2 =30.3%), and additional sensitivity analyses did not significantly alter our findings. Only 1 study had a low risk of bias across all domains.
Conclusion: The results of this meta-analysis suggest that selected adult patients with IgA-tTG ≥10×ULN and a moderate to high pretest probability of celiac disease could be diagnosed without undergoing invasive endoscopy and duodenal biopsy.
Keywords: Adult; Biopsy; Celiac Disease; Humans; Immunoglobulin A; Transglutaminases.
Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved.
Comment in
-
Moving Away From Biopsy Confirmation of Celiac Disease.Gastroenterology. 2024 Apr;166(4):557-558. doi: 10.1053/j.gastro.2024.01.037. Epub 2024 Feb 1. Gastroenterology. 2024. PMID: 38309630 No abstract available.
Similar articles
-
Evaluation of BioPlex 2200 tTG-IgA Diagnostic Performance for Serology-Based Diagnosis of Celiac Disease.Am J Clin Pathol. 2022 Jan 6;157(1):136-139. doi: 10.1093/ajcp/aqab104. Am J Clin Pathol. 2022. PMID: 34542555
-
Identification of Pediatric Patients With Celiac Disease Based on Serology and a Classification and Regression Tree Analysis.Clin Gastroenterol Hepatol. 2017 Mar;15(3):396-402.e2. doi: 10.1016/j.cgh.2016.10.035. Epub 2016 Nov 12. Clin Gastroenterol Hepatol. 2017. PMID: 27847281 Free PMC article.
-
Validation of Antibody-Based Strategies for Diagnosis of Pediatric Celiac Disease Without Biopsy.Gastroenterology. 2017 Aug;153(2):410-419.e17. doi: 10.1053/j.gastro.2017.04.023. Epub 2017 Apr 28. Gastroenterology. 2017. PMID: 28461188 Clinical Trial.
-
Tests for Serum Transglutaminase and Endomysial Antibodies Do Not Detect Most Patients With Celiac Disease and Persistent Villous Atrophy on Gluten-free Diets: a Meta-analysis.Gastroenterology. 2017 Sep;153(3):689-701.e1. doi: 10.1053/j.gastro.2017.05.015. Epub 2017 May 22. Gastroenterology. 2017. PMID: 28545781 Free PMC article. Review.
-
Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis.Am J Gastroenterol. 2017 Jan;112(1):65-76. doi: 10.1038/ajg.2016.466. Epub 2016 Oct 18. Am J Gastroenterol. 2017. PMID: 27753436 Review.
Cited by
-
Celiac disease and nonceliac enteropathies.Curr Opin Gastroenterol. 2024 Nov 1;40(6):464-469. doi: 10.1097/MOG.0000000000001048. Epub 2024 Jun 14. Curr Opin Gastroenterol. 2024. PMID: 39360696 Review.
-
Non-biopsy Strategy for the Diagnosis of Celiac Disease in Adults: A Narrative Review.Turk J Gastroenterol. 2024 Aug 2;35(8):589-598. doi: 10.5152/tjg.2024.24092. Turk J Gastroenterol. 2024. PMID: 39150308 Free PMC article. Review.
-
Role of endoscopy in the diagnosis of coeliac disease: a narrative review.Transl Gastroenterol Hepatol. 2024 May 9;9:51. doi: 10.21037/tgh-23-122. eCollection 2024. Transl Gastroenterol Hepatol. 2024. PMID: 39091660 Free PMC article. Review.
-
Evolution in coeliac disease diagnosis and management.JGH Open. 2024 Jul 2;8(7):e13107. doi: 10.1002/jgh3.13107. eCollection 2024 Jul. JGH Open. 2024. PMID: 38957478 Free PMC article. Review.
-
Preparation and Immunochemical Characterization of a Water-Soluble Gluten Peptide Fraction for Improving the Diagnosis of Celiac Disease.Nutrients. 2024 Mar 5;16(5):742. doi: 10.3390/nu16050742. Nutrients. 2024. PMID: 38474870 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
